OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) and Eyetech Pharmaceuticals, Inc. (NASDAQ: EYET) today announced that the closing of the OSI acquisition of Eyetech will occur on Monday, November...
Stockholders Overwhelmingly Approve Merger NEW YORK, Nov. 10 /PRNewswire-FirstCall/ -- Eyetech Pharmaceuticals, Inc. (NASDAQ:EYET) provided an update today on the status of its pending...
Company achieves operating profitability, excluding certain charges, based on total revenue of $67.4 million and net product revenue of $55.5 million NEW YORK, Oct. 31 /PRNewswire-FirstCall/...
Phase 2 study of Macugen in diabetic macular edema (DME) published in the October issue of Ophthalmology NEW YORK, Oct. 17 /PRNewswire-FirstCall/ .- Eyetech Pharmaceuticals, Inc. (NASDAQ:EYET...
Retrospective, subgroup analyses of the VISION study suggest that treatment of early disease with Macugen may further reduce the risk of vision loss associated with neovascular AMD compared to the...
NEW YORK, Sept. 16 /PRNewswire-FirstCall/ -- Eyetech Pharmaceuticals, Inc. (NASDAQ:EYET) announced today that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee...
Acquisition Projected to be Accretive and Generate Combined 2006 Revenues of Over $600 Million MELVILLE, N.Y. and NEW YORK, Aug. 21 /PRNewswire-FirstCall/ -- OSI Pharmaceuticals, Inc...
OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) and Eyetech Pharmaceuticals, Inc. (NASDAQ: EYET) today announced that they have entered into a definitive merger agreement whereby OSI has agreed...
Award recognizes Macugen's breakthrough technology as the first anti- angiogenic treatment approved in ophthalmology and the first aptamer therapy approved by the FDA NEW YORK, Aug. 9...
Eyetech Reports Second Quarter 2005 Financial Results - Gross Product Revenue for Macugen(R) (pegaptanib sodium injection) increased to $50 million in the second quarter from $25 million in the...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約